Several limitations deriving from this study should be considered: first, the small number of clinical cases collected requires further verification of the stability and universality of our findings; second, intervention methods remain immature, as MCPIP1 knockdown was performed in animal models and preclinical safety evaluation is lacking; third, its mechanism of MCPIP1 activity requires clarification, and whether MCPIP1 in PC is regulated by other molecules or exerts subtype‐specific differences may affect clinical application. Here, ZC3H12A is linked to pachyonychia congenita.